SAR445088 (formerly BIVV020) ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 14 | 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー | 2 |
14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー
臨床試験数 : 175 / 薬物数 : 161 - (DrugBank : 41) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 24
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004006-54-DE (EUCTR) | 23/06/2021 | 08/03/2021 | Proof-of-concept study for BIVV020 in chronic inflammatory demyelinating polyneuropathy (CIDP) | Phase 2, multicenter, open-label, non-randomized,proof-of-concept study evaluating the efficacy, safety,and tolerability of BIVV020 in adults with chronicinflammatory demyelinating polyneuropathy (CIDP) | Chronic inflammatory demyelinatingpolyneuropathy MedDRA version: 20.0;Level: LLT;Classification code 10077384;Term: Chronic inflammatory demyelinating polyneuropathy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR445088 (formerly BIVV020) Other descriptive name: BIVV020 | Sanofi-Aventis Recherche & Développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Phase 2 | France;Poland;Netherlands;Germany;Italy | ||
| 2 | EUCTR2020-004006-54-PL (EUCTR) | 29/04/2021 | 31/03/2021 | Proof-of-concept study for BIVV020 in chronic inflammatory demyelinating polyneuropathy (CIDP) | Phase 2, multicenter, open-label, non-randomized,proof-of-concept study evaluating the efficacy, safety,and tolerability of BIVV020 in adults with chronicinflammatory demyelinating polyneuropathy (CIDP) | Chronic inflammatory demyelinatingpolyneuropathy MedDRA version: 20.0;Level: LLT;Classification code 10077384;Term: Chronic inflammatory demyelinating polyneuropathy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: SAR445088 (formerly BIVV020) Other descriptive name: BIVV020 | Sanofi-Aventis Recherche & Développement | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Phase 2 | France;Poland;Germany;Netherlands;Italy |